



## ENGINEERING A BETTER DRUG DEVELOPMENT PROCESS THROUGH SCIENTIFIC EXCELLENCE

**Aptuit, Inc.**  
**Two Greenwich Office Park**  
**Greenwich, CT 06831**  
**Tel: (203) 422-6600**  
**Fax: (203) 422-0266**  
**Web: [www.apptuit.com](http://www.apptuit.com)**  
**E-mail: [info@apptuit.com](mailto:info@apptuit.com)**



### Vital Statistics

**Year Founded:** 2005

**Number of Employees:** over 2700 worldwide

**Key Personnel:** Timothy C. Tyson, Executive Chairman and Chief Executive Officer; Frank J. Wright, Vice Chairman and Founder; Stuart E. Needleman, President, API Development and Manufacturing; Jeffrey Wilson, President, Pharmaceutical Development and Manufacturing; Gerry Hepburn, President of Clinical Operations; Thierry Amat, Chief Financial Officer; Don Britt, Senior Vice President, Corporate Quality Assurance; John Fikre, General Counsel; William Kerns, President, Aptuit Consulting; Dr. C. Satyanarayana, Chief Executive Officer, Aptuit Laurus.

### Who We Are

FOUNDED IN 2005, APTUIT IS A pharmaceutical services company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. Since its inception, Aptuit has been engineering a better drug development process by amassing a staff of consummate professionals, breakthrough technologies, facilities and new ideas to offer its clients seamless and globally integrated services.

Aptuit is structured to focus on three major business units - API Development and Manufacturing, Pharmaceutical Development and Manufacturing and Clinical Operations - as well as offering the services of an independent Consulting group. Clients may elect to use all of the comprehensive services of these units, end to end, or select distinctive parts of the mix as needed.

From its earliest days, Aptuit has been assembling some of the industry's foremost professionals with specific expertise across a broad range of disciplines. Concurrently, Aptuit implemented a series of strategic acquisitions that began in 2005 with the Quintiles Early Development and Packaging business units and Almedica. In November of the same year, an acquisition agreement with InfoPro Solutions led to the launching of Aptuit's Informatics, featuring the industry-standard Clinicopia® Suite. In May, 2006, Aptuit Consulting was launched as a result of the acquisition of Pharma Consulting, Inc.

The acquisition of EaglePicher Pharmaceutical Services in February, 2007, added Active Pharmaceutical Ingredient (API) development and drug substance manufacturing capabilities to Aptuit's growing roster of services. At the same time, Aptuit acquired SSCI, the leading solid-state chemistry company focused on crystallization, characterization and chemistry of solid material. These important ventures streamlined Aptuit's API development and supply process and offered customers a better understanding of their compound's characterization profile earlier on in the process, minimizing delays and reducing the time and cost of commercialization. In 2007, Aptuit entered into a phased acquisition of Laurus Labs in Hyderabad, India, transforming it into Aptuit

Laurus. The integration of small scale development facilities in the United States and Europe with commercial scale manufacturing in India brings comprehensive global service to pharmaceutical and biotechnical innovators. For clients, there is a unique advantage of round-the-clock services from Aptuit through its combined global resources in Europe, Asia and the United States.

Aptuit continues its unrelenting commitment to servicing its clients as a world class provider of pharmaceutical services. In these challenging times, the company is dedicated to providing solutions that help clients throughout the drug development continuum from discovery to proof of concept and launch.

### Major Markets

Aptuit provides a comprehensive suite of drug development services and competencies to more than 700 pharmaceutical and biotechnology companies worldwide from 18 locations.

### Services Offered

- **API Development and Manufacturing:** most complete global API provider, featuring solid-state chemistry, radiolabeling, process R&D, preclinical and clinical supply, and manufacture of High Potent and Cytotoxic compounds
- **Preclinical and Clinical Technologies:** preclinical services for aiding lead candidate selection in the form of efficacy pharmacology and early drug metabolism support, followed by clinical services that include submission of successful regulatory findings, including toxicology studies, safety pharmacology studies and supporting bioanalytical and analytical studies
- **Pharmaceutical Sciences:** vast, quality-driven global network of advanced GLP/GMP laboratory and manufacturing to formulate a wide range of dosage forms; uniquely integrated preclinical and pharmaceutical development, including clinical trial manufacture and supply to reduce time to clinic and accelerate commercial success
- **Physical and Analytical Chemistry:** problem solving expertise for drug substance and product development, stability, analytical methods, intellectual property and diverse solid-state chemistry control issues
- **Clinical Packaging and Logistics:** comprehensive services featuring global distribution channels; full service GMP-compliant procedures across all phases of clinical testing, using most advanced technology and equipment
- **Consulting:** unique global consultancy team of Drug Development Experts, supporting customers from preclinical testing to commercialization through regulation
- **Aptuit INDIGO™:** exclusive, customized drug development method to accelerate early drug candidates by reducing the time from API to IND submission, at times as brief as 26 weeks